ALGN ALIGN TECHNOLOGY INC
Orthopedic, Prosthetic & Surgical Appliances & Supplies · Nasdaq · SEC CIK 1097149 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY4.4%
TTM net income YoY30.0%
TTM EPS YoY32.9%
Revenue 3-yr CAGR3.0%
Net income 3-yr CAGR10.7%
Margins
Gross margin69.1%
Operating margin14.9%
Net margin11.8%
FCF margin14.5%
EBITDA margin20.6%
Returns
ROE11.9%
ROA7.7%
ROIC (approx.)15.5%
Asset turnover0.65x
Leverage & solvency
Liabilities / assets34.0%
Debt / equity0.00x
Current ratio1.42x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.52x
Accruals ratio-4.0%
Payout ratio—
Capex / revenue3.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $4.03B | $4.00B |
| Cost of revenue | $1.32B | $1.20B |
| Gross profit | $2.71B | $2.80B |
| R&D expense | $369.91M | $364.20M |
| SG&A expense | $1.76B | $1.76B |
| Operating income | $545.75M | $607.63M |
| Pretax income | $585.29M | $608.96M |
| Income tax | $174.94M | $187.60M |
| Net income | $410.35M | $421.36M |
| EBITDA | $783.19M | $752.66M |
| EPS (basic) | 5.66 | 5.63 |
| EPS (diluted) | 5.65 | 5.62 |
| Weighted avg. shares (diluted) | 72.59M | 74.99M |
| Balance sheet | ||
| Cash & equivalents | $1.09B | $1.04B |
| Short-term investments | — | $0 |
| Receivables | $1.10B | $995.68M |
| Inventory | $226.34M | $254.29M |
| Current assets | $2.62B | $2.49B |
| PP&E, net | $1.13B | $1.27B |
| Goodwill | $491.83M | $442.63M |
| Intangibles | $93.93M | $103.49M |
| Total assets | $6.23B | $6.21B |
| Current liabilities | $1.92B | $2.04B |
| Total liabilities | $2.18B | $2.36B |
| Shareholders' equity | $4.05B | $3.85B |
| Shares outstanding | 71.36M | 73.85M |
| Cash flow statement | ||
| Operating cash flow | $593.22M | $738.23M |
| Capital expenditure | $102.44M | $115.58M |
| Free cash flow | $490.78M | $622.65M |
| Investing cash flow | -$112.44M | -$254.91M |
| Financing cash flow | -$464.58M | -$355.72M |
| Depreciation & amortization | $237.44M | $145.03M |
| Stock-based compensation | $185.87M | $173.70M |
| Share buybacks | $465.94M | $352.88M |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.